本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

神经分泌生物科学

131.50
-3.6300-2.69%
成交量:43.45万
成交额:5,766.01万
市值:130.14亿
市盈率:44.47
高:136.25
开:135.49
低:131.21
收:135.13
数据加载中...
2025/07/10

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/07/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/05/30

重要事件披露

Form 8-K - Current report
2025/05/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/05/22

重要事件披露

Form 8-K - Current report
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/21

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/05/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/05/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]